Cardiac amyloidosis: vutrisiran appears to better preserve perceived physical abilities

A questionnaire to clarify the perceived benefit

The HELIOS-B trial compared vutrisiran with placebo, with participants randomly assigned and under double-blind conditions. This analysis examines changes from baseline to 30 months for each of the 23 components of the Kansas City Cardiomyopathy Questionnaire, or KCCQ. Scores range from 0, the least favorable, to 100, the most favorable.

Of the trial’s 654 participants, 486 completed the questionnaire at baseline and at 30 months. Their mean age was 75 years, and 93% were men. The findings therefore mainly describe an older male population with this heart disease, not healthy people looking to improve their endurance.

Differences mainly in physical limitations

Changes were more favorable with vutrisiran than with placebo for most questionnaire components. The median difference between groups was 3.8 points, with differences ranging from −0.9 to +7.6 points depending on the component. This median is calculated across questionnaire components: it does not represent the gain for an average patient.

The largest differences concerned hurrying or jogging, walking on level ground, and feeling discouraged because of heart failure. This helps identify the aspects of daily life that may be better preserved. However, the abstract does not establish how many patients experienced a clinically meaningful improvement.

Similar or more favorable results were also reported in patients who were not taking tafamidis at baseline. This observation does not constitute a direct comparison between the two treatments.

An 11-year statistical gap, not rejuvenation

The researchers also modeled the relationship between age and the overall questionnaire score at 30 months. The shift associated with vutrisiran corresponded to approximately 11 years in this statistical relationship, with a confidence interval of 3 to 20 years.

This finding means neither an 11-year rejuvenation nor an equivalent gain in life expectancy. It expresses a difference in perceived health status scores in relation to age. When interpreting the benefit, the specific limitations reported by patients remain more informative than this conversion into years.

What we can take away

This analysis suggests that the benefit of vutrisiran on perceived health status relates particularly to physical limitations and quality of life. It does not demonstrate a rejuvenating effect or improved athletic performance.